Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ascorbic acid** is vitamin C, a small-molecule water-soluble reducing agent and essential nutrient. In the Clifford Hospital-sponsored NSCLC program, pharmacologic-dose intravenous ascorbic acid was investigated alongside local modulated electro-hyperthermia and supportive care for stage III-IV non-small cell lung cancer. At high intravenous concentrations, ascorbate can undergo redox cycling and promote extracellular hydrogen peroxide generation and oxidative stress, a non-target-directed mechanism proposed to preferentially damage susceptible tumor cells. The registered Phase I-II study was NCT02655913. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02655913))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ascorbic acid (Clifford Hospital).